Amneal Pharmaceuticals, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03168L1052
USD
11.94
-0.26 (-2.09%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Amneal Pharmaceuticals, Inc. stock-summary
stock-summary
Amneal Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Amneal Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. It operates in two segments, which include Generics and Specialty Pharma. The Generics is focused on the development, manufacture, sale and distribution of the Company's generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their drug names. The Specialty Pharma is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease (PD), post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.
Company Coordinates stock-summary
Company Details
400 Crossing Blvd Fl 3 , BRIDGEWATER NJ : 08807-2863
stock-summary
Tel: 1 908 4096700
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 61 Schemes (14.75%)

Foreign Institutions

Held by 107 Foreign Institutions (4.31%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Paul Meister
Independent Chairman of the Board
Mr. Chirag Patel
President, Co-Chief Executive Officer, Director
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Mr. Gautam Patel
Director
Ms. Emily Alva
Independent Director
Mr. J. Kevin Buchi
Independent Director
Mr. Jeffrey George
Independent Director
Mr. John Kiely
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
725 Million
(Quarterly Results - Jun 2025)
Net Profit:
36 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,906 Million (Small Cap)

stock-summary
P/E

58.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-21.41

stock-summary
Return on Equity

-53.04%

stock-summary
Price to Book

-25.92